As someone who has lived with spinal muscular atrophy for all 30 years of my life, I was perplexed and disappointed that the recent approval of Novartis’ gene therapy Zolgensma was immediately overshadowed by outrage over the drug’s price: $2.125 million

Quick Read

Cheap and simple medical devices could improve performance and lower health-care costs, but first they have to overcome deeply rooted biases. With comments from our Nancy Kass

Quick Read

The promise of personalized medicine is a pretty big one: Tailoring treatments to a patient’s genes, their environment or their lifestyle, the thinking goes, will result in treatments that are much more likely to work. The same disease can manifest differently in different people, so why treat patients with a one-size-fits-all-approach?

Quick Read

The approval of gene therapy for leukemia, expected in the next few months, will open the door to a radically new class of cancer treatments

Quick Read

Reshma Ramachandran and our Zackary Berger voice concerns about the impact of the 21st Century Cures Act on the FDA should it become law

Quick Read

Earlier this evening, the House of Representatives released the most recent draft of the 21st Century Cures Act, which has ballooned from a 200-page discussion draft in April 2015 to a 996-page draft version today

Quick Read

Over the years, citizen scientists have provided vital data and contributed in invaluable ways to various scientific quests. But they’re typically relegated to helping traditional scientists complete tasks the pros don’t have the time or resources to deal with on their own. Citizens are asked to count wildlife, for instance, or classify photos that are of interest to the lead researchers

Quick Read

We’ve been ignoring two important lessons from the CRISPR/Cas9 patent dispute: patent systems no longer fit the realities of how science works, and patents give their owners significant control over the fate and shape of technologies

Quick Read